The primary function of the Clinical Pharmacology Shared Resource (CPSR) is to support NCCC investigators in the design, performance, data analysis, and interpretation of clinical pharmacology objectives in preclinical (ex-vivo and in vivo), clinical, chemoprevention, and epidemiological studies, at as low a cost as possible. The CPSR has modified its staffing since the last submission such that it now consists of one clinical pharmacologist, one research assistant and a part of a second research assistant, a research nursing resource, and a part of a research pharmacist. The major CPSR services include: 1) Central processing for biological tissue samples (e.g. cells/tumor tissue/plasma/saliva/urine) and cell samples obtained as part of approved clinical and epidemiological protocols: these services include, but are not limited to, sampleprocessing (including processing peripheral blood mononuclear cells), logging and storage, aliquoting, and mail-outs;2) (a) Development of novel drug assays (when such assays are not routinely available) using either HPLC (UV/Fluorescence detection) or LC-MS/MS methodology, (b) Performance of drugconcentration measurements in biological fluids and tissues for preclinical and clinical oncology studies;3) (a) Consultation concerning study design and pharmacokinetic and pharmacodynamic hypothesis-testing in preclinical and clinical studies, (b) Pharmacokinetic and pharmacodynamic data analysis and modeling from pre-clinical and clinical studies;4) Phase-l and proof-of-principle study research nursing support services;5) Pharmacogenomic (PGx) assays and expertise applied to cancer drug research;and 6) Research Pharmacy Service for oncology drug research with commercially available and investigational new drugs. The CPSR currently provides 13 NCCC investigators with services valued at $118,881 in chargebacks for FY 2007. NCCC members represent 76% of the total number of investigators using this facility at Dartmouth, and their usage constitutes 87% of total CPSR usage. The total chargebacks for this core were $130,161 during FY2007, and the total operating budget was $397,951, requiring $267,789 in non-chargeback subvention, which is derived from a combination of the NCCC CCSG and chargebacks to other sponsored projects. This shared resource is requesting a budget of $109,722 from the NCCC CCSG for the first year of this competitive renewal (2008-09), representing a level comparable to the current year's support, which will provide 39% of its non-chargeback subvention needs, while the majority of costs are recovered through chargebacks and other institutional support. This core grant budget and the other subvention sources primarily underwrite a portion of the chargeback costs to individual NCCC investigators and provide administrative support for oversight of this shared resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023108-32
Application #
8015000
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
32
Fiscal Year
2010
Total Cost
$161,212
Indirect Cost
Name
Dartmouth College
Department
Type
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Durand, Marie-Anne; Yen, Renata West; O'Malley, A James et al. (2018) What matters most: protocol for a randomized controlled trial of breast cancer surgery encounter decision aids across socioeconomic strata. BMC Public Health 18:241
Soneji, Samir S; Sung, Hai-Yen; Primack, Brian A et al. (2018) Quantifying population-level health benefits and harms of e-cigarette use in the United States. PLoS One 13:e0193328
Tosteson, Anna N A; Yang, Qian; Nelson, Heidi D et al. (2018) Second opinion strategies in breast pathology: a decision analysis addressing over-treatment, under-treatment, and care costs. Breast Cancer Res Treat 167:195-203
Molodtsov, Aleksey; Turk, Mary Jo (2018) Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity. Front Immunol 9:2810
Courtney, Andrea L; Rapuano, Kristina M; Sargent, James D et al. (2018) Brain Reward Responses Are Behaviorally Relevant: The Authors Respond. J Stud Alcohol Drugs 79:41-42
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Lin, Anping; Yin, Juan; Cheng, Chao et al. (2018) Decreased expression of FOXA2 promotes eutopic endometrial cell proliferation and migration in patients with endometriosis. Reprod Biomed Online 36:181-187
Elder, David E; Piepkorn, Michael W; Barnhill, Raymond L et al. (2018) Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation. J Am Acad Dermatol 79:52-59.e5
Pernas, Sonia; Martin, Miguel; Kaufman, Peter A et al. (2018) Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol 19:812-824
Kumar, Nishant; Tafe, Laura J; Higgins, John H et al. (2018) Identifying Associations between Somatic Mutations and Clinicopathologic Findings in Lung Cancer Pathology Reports. Methods Inf Med 57:63-73

Showing the most recent 10 out of 1911 publications